Alopecia Areata: Causes, Treatments, and Prognosis

Alopecia areata (AA) is an autoimmune disorder in which the immune system mistakenly attacks hair follicles, causing them to shrink and dramatically slow hair production:

• Autoimmune mechanism: T-lymphocytes infiltrate the hair follicle bulb, disrupting the hair growth cycle. The follicles enter a forced resting phase but are not destroyed — this is why regrowth is possible.
• Genetic component: First-degree relatives of people with AA have a 5-10x increased risk. Genome-wide association studies have identified over 14 genetic loci associated with AA, many shared with other autoimmune diseases.
• Associated conditions: AA is more common in people with other autoimmune disorders including thyroid disease (25% of AA patients), vitiligo, type 1 diabetes, and atopic dermatitis.
• Triggers: While the underlying cause is genetic/immunological, episodes may be triggered by physical or emotional stress, viral infections, or hormonal changes. A 2021 study in Nature Immunology identified specific immune signaling pathways (JAK-STAT) that become aberrantly activated.

AA affects males and females equally and can occur at any age, though 60% of cases first appear before age 20.

Treatment for alopecia areata has been revolutionized by JAK inhibitors, but multiple options exist depending on severity:

For limited patches (less than 50% scalp involvement):

• Intralesional corticosteroid injections: Triamcinolone injected directly into patches every 4-6 weeks. First-line treatment with 60-70% response rate for limited AA.
• Topical corticosteroids: High-potency steroids (clobetasol) applied daily. Less effective than injections but non-invasive.
• Topical immunotherapy (DPCP): Induces an allergic contact dermatitis that may redirect the immune attack away from follicles. Response rates of 50-70% reported.

For extensive AA (more than 50% involvement):

• Baricitinib (Olumiant): First FDA-approved systemic treatment for AA (2022). In the BRAVE-AA1 trial, 39% of patients achieved 80%+ scalp coverage at 36 weeks vs. 6% placebo.
• Ritlecitinib (Litfulo): FDA-approved in 2023 for adolescents and adults. JAK3/TEC family kinase inhibitor.

Upload your dermatologist's diagnosis and treatment plan to WAYJET's Medical Report Analyzer for an organized summary of your condition and treatment options.

The course of alopecia areata is highly variable and difficult to predict:

• Spontaneous recovery: Approximately 50% of patients with limited patches experience complete regrowth within 1 year without treatment. However, recurrence is common — 85% of patients experience at least one relapse.
• Prognostic factors (worse outcome): Childhood onset, ophiasis pattern (band-like loss around the scalp margins), extensive involvement (>50% of scalp), nail changes, family history of AA, and concurrent atopic disease.
• Alopecia totalis/universalis: Complete loss of scalp hair (totalis) or all body hair (universalis) occurs in 5-10% of cases and has a lower spontaneous recovery rate (10-20%).

Mental health considerations are significant:

• A 2021 systematic review in the Journal of the American Academy of Dermatology found 39% of AA patients had clinically significant anxiety and 29% had depression
• Support groups (National Alopecia Areata Foundation) and psychological support are important components of comprehensive care
• Children with AA may face bullying — school education programs can help

Even in severe cases, the follicles remain alive beneath the skin. New immune-targeted therapies continue to emerge, offering hope for increasingly effective treatments.